Articles published by Belite Bio, Inc
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 12, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
November 05, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
October 14, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
September 10, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in Three Upcoming Investor Conferences
September 03, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
September 01, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 09, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
August 05, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
June 12, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 08, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces $25 Million Registered Direct Offering
April 25, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023
From Belite Bio, Inc
Via GlobeNewswire
Tickers
BLTE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.